Skip to main content
Premium Trial:

Request an Annual Quote

WaferGen's Q3 Revenues Plummet; Layoffs Planned

NEW YORK (GenomeWeb News) – WaferGen Biosystems today reported a steep drop in its third-quarter revenues and a planned cut of 24 percent of its workforce as part of a revised plan to increase adoption of its SmartChip System.

The Fremont, Calif.-based firm reported total revenues of $89,088 for the quarter ended Sept. 30, compared to $633,241 for the third quarter of 2010.

The firm is in the midst of retooling its commercialization strategy for the SmartChip Real-Time PCR System. The latest results follow a similar sharp decline in second-quarter sales.

"During the third quarter of 2011 we implemented a new commercial strategy to address the rapidly changing needs of the life sciences research market and to better anticipate future needs of researchers," WaferGen COO Mona Chadha said in a statement. "We have decided to invest significantly in scientific resources focused on a strategy to engage an array of key opinion leaders in our target market, enabling the profiling and validation of high-value genomic targets."

Though the firm provided scant details of the new commercialization strategy, it said that it would trim its workforce by 24 percent — a move that is expected to result in a $1.3 million annual reduction in operating expenses. It will take a one-time charge related to the job cuts of approximately $400,000 in the fourth quarter.

WaferGen posted a profit of $3.6 million, or $.03 per share, compared to a net loss of $5.2 million, or $.14 per share, for the third quarter of 2010. The results for Q3 2011 were impacted by a $7.5 million gain on the revaluation of promissory notes and a nearly $1.1 million gain on the revaluation of warrants. Its net loss attributable to common stockholders was $19.2 million, or $.46 per share, compared to a loss attributable to common stockholders of $9.7 million, or $.27 for Q3 2010.

WaferGen's R&D costs for the quarter declined 5 percent to $1.9 million from $2 million, while its SG&A expenses increased 16 percent to $2.2 million from $1.9 million.

The firm finished the quarter with $19.8 million in cash and cash equivalents. In May the company completed a private placement financing of $30.6 million in equity and debt with three institutional life science investors, as well as certain members of the Board of Directors and management.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.